Sevion Therapeutics

About:

Sevion is a biopharmaceutical company which discovers and develops entirely new therapeutic classes for the treatment of cancer.

Website: http://www.seviontherapeutics.com/

Twitter/X: Senesco

Top Investors: Perceptive Advisors, The Hewlett Fund, InterGroup, Iroquois Capital, Heights Capital Management

Description:

Sevion is a biopharmaceutical company which discovers, develops and acquires innovative product candidates for the treatment of cancer and immunological diseases. The Company is advancing a pipeline of proprietary and partnered product candidates that leverages its unique antibody technology platforms. The Company’s antibody pipeline is being developed from technology that allows for the discovery of innovative biologic therapies to previously inaccessible targets, such as multispanning membrane proteins and ion channels that play an important role in multiple diseases. The Company also developed the first protein nanocage system allowing delivery of nucleic acids and other payloads to target cells.

Total Funding Amount:

$16.2M

Estimated Revenue Range:

$50M to $100M

Headquarters Location:

San Diego, California, United States

Founded Date:

1964-01-01

Contact Email:

info(AT)seviontherapeutics.com

Founders:

Shmuel Tuvia, Silvia Noiman

Number of Employees:

11-50

Last Funding Date:

2015-05-19

IPO Status:

Delisted

Industries:

© 2025 bioDAO.ai